Your browser is no longer supported. Please, upgrade your browser.
RDY Dr. Reddy's Laboratories Limited monthly Stock Chart
Dr. Reddy's Laboratories Limited
Index- P/E40.53 EPS (ttm)1.50 Insider Own27.70% Shs Outstand165.80M Perf Week11.54%
Market Cap10.00B Forward P/E29.04 EPS next Y2.09 Insider Trans0.00% Shs Float121.87M Perf Month16.25%
Income249.30M PEG3.19 EPS next Q0.54 Inst Own13.80% Short Float1.22% Perf Quarter20.32%
Sales2.41B P/S4.15 EPS this Y3.80% Inst Trans0.54% Short Ratio7.39 Perf Half Y39.19%
Book/sh13.03 P/B4.67 EPS next Y5.65% ROA8.00% Target Price47.58 Perf Year66.21%
Cash/sh2.25 P/C27.02 EPS next 5Y12.70% ROE12.10% 52W Range33.33 - 60.95 Perf YTD49.83%
Dividend0.33 P/FCF29.19 EPS past 5Y-2.00% ROI9.90% 52W High-1.44% Beta0.51
Dividend %0.54% Quick Ratio1.20 Sales past 5Y3.30% Gross Margin54.80% 52W Low80.23% ATR1.32
Employees21650 Current Ratio1.70 Sales Q/Q14.90% Oper. Margin9.00% RSI (14)71.93 Volatility2.24% 1.80%
OptionableYes Debt/Eq0.20 EPS Q/Q-12.70% Profit Margin10.40% Rel Volume0.66 Prev Close60.80
ShortableYes LT Debt/Eq0.04 EarningsJul 29 BMO Payout- Avg Volume201.45K Price60.07
Recom4.00 SMA2010.36% SMA5012.46% SMA20032.04% Volume87,249 Change-1.20%
Jan-28-20Downgrade CLSA Buy → Outperform
Jan-27-20Downgrade CLSA Buy → Outperform
Jan-09-20Upgrade Citigroup Sell → Buy
Nov-04-19Downgrade BofA/Merrill Buy → Neutral
Sep-04-19Upgrade Credit Suisse Underperform → Outperform
Jul-01-19Upgrade Macquarie Neutral → Outperform
Jun-20-19Initiated Deutsche Bank Hold
Jun-11-19Initiated Barclays Equal Weight $39
May-20-19Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-19-19Upgrade CLSA Outperform → Buy
Jan-17-19Downgrade Citigroup Neutral → Sell
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-31-17Upgrade CLSA Underperform → Outperform
Jul-28-17Downgrade CLSA Underperform → Sell
Jul-27-16Downgrade Jefferies Hold → Underperform
Jul-27-16Downgrade HSBC Securities Hold → Reduce
Feb-10-16Upgrade Credit Agricole Underperform → Buy
Nov-10-15Downgrade Citigroup Buy → Neutral
Jan-21-11Initiated HSBC Securities Overweight
Jan-19-10Downgrade Deutsche Bank Hold → Sell
Jul-29-20 06:47AM  
Jul-27-20 08:31AM  
Jul-20-20 07:59AM  
Jul-14-20 04:45AM  
Jul-08-20 08:59AM  
Jul-06-20 07:07AM  
Jul-05-20 05:05PM  
Jul-01-20 04:10AM  
Jun-19-20 05:39AM  
Jun-16-20 01:48AM  
Jun-15-20 10:32AM  
Jun-13-20 05:15AM  
Jun-12-20 07:44AM  
Jun-11-20 02:45PM  
Jun-10-20 05:49AM  
May-21-20 09:56AM  
May-20-20 03:15PM  
May-07-20 04:50AM  
May-06-20 01:15PM  
Apr-27-20 03:07AM  
Apr-24-20 11:42AM  
Apr-17-20 08:55AM  
Apr-14-20 05:22AM  
Apr-13-20 06:17PM  
Apr-08-20 10:28AM  
Mar-27-20 06:45PM  
Mar-26-20 02:03PM  
Mar-22-20 08:29PM  
Mar-21-20 09:29AM  
Mar-20-20 01:38AM  
Mar-19-20 02:50AM  
Mar-17-20 05:53AM  
Mar-06-20 06:50AM  
Feb-27-20 04:03AM  
Feb-14-20 11:41AM  
Feb-07-20 03:02AM  
Feb-06-20 08:30AM  
Jan-30-20 07:00AM  
Jan-28-20 10:20AM  
Jan-27-20 04:32AM  
Jan-10-20 10:14AM  
Dec-30-19 04:57AM  
Dec-20-19 04:41AM  
Dec-13-19 12:00PM  
Dec-06-19 03:29AM  
Dec-04-19 02:49AM  
Nov-22-19 04:48AM  
Nov-15-19 08:42AM  
Nov-13-19 09:22AM  
Nov-11-19 08:42AM  
Nov-04-19 09:10AM  
Nov-01-19 04:29AM  
Oct-23-19 04:42AM  
Oct-17-19 04:55PM  
Oct-14-19 06:40AM  
Sep-30-19 05:45PM  
Sep-23-19 11:18AM  
Sep-20-19 05:14PM  
Sep-19-19 11:32AM  
Sep-17-19 11:29AM  
Sep-16-19 10:00AM  
Sep-11-19 07:18AM  
Sep-06-19 09:07AM  
Sep-04-19 09:15AM  
Sep-03-19 06:52AM  
Aug-28-19 08:36AM  
Aug-26-19 08:38AM  
Aug-20-19 02:59AM  
Aug-19-19 04:20AM  
Aug-01-19 10:41AM  
Jul-31-19 04:05PM  
Jul-30-19 09:14AM  
Jul-29-19 09:15AM  
Jul-23-19 06:27AM  
Jul-20-19 06:21AM  
Jul-19-19 02:29AM  
Jul-12-19 11:40PM  
Jul-10-19 05:13AM  
Jul-09-19 03:23AM  
Jul-03-19 04:42AM  
Jun-28-19 03:16PM  
Jun-25-19 10:33AM  
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology. The company was founded in 1984 and is headquartered in Hyderabad, India.